Skip to main content

Ovarian Cancer Clinical Trials

Review the ovarian cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 201-225 of 327

A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Status: Active
Location: See ClinicalTrials.gov
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Status: Active
Location: Wayne State University/Karmanos Cancer Institute, Detroit, Michigan
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers
Status: Active
Location: See ClinicalTrials.gov
A Study of HB0045 Injection in Patients With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Status: Active
Location: See ClinicalTrials.gov
Study of DF6215 in Patients with Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Study Evaluating MM-310 in Patients With Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies
Status: Active
Location: See ClinicalTrials.gov
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Study of BND-35 in Participants With Advanced Solid Tumors
Status: Active
Location: University of Colorado, Denver, Colorado
A Study of DF6002 Alone and in Combination With Nivolumab
Status: Active
Location: See ClinicalTrials.gov
Acetylcysteine for the Mitigation of Chemotherapy-Related Cognitive Impairment in Ovarian Cancer Patients Receiving Platinum-Based Therapy
Status: Approved
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
A Cancer Vaccine (NY-ESO-1) and Immunotherapy (Toripalimab) for the Treatment of Stage III/IV Platinum-Refractory or Resistant Ovarian Cancer
Status: Temporarily Closed to Accrual
Location: 2 locations
Targeted CAR-T Cell Therapy (IVS-3001) for the Treatment of Previously Treated Locally Advanced Unresectable or Metastatic HLA-G Positive Solid Tumors
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
FRalphaDC Vaccine with Pembrolizumab for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FRAPPE Trial
Status: Temporarily Closed to Accrual
Location: 3 locations
Testing the Combination of ZEN003694 and Nivolumab with or without Ipilimumab in Solid Tumors
Status: Temporarily Closed to Accrual
Location: 6 locations
Niraparib and Copanlisib in Treating Patients with Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Selumetinib and Olaparib in Treating Participants with Relapsed or Refractory and Advanced Endometrial, Ovarian, or Other Solid Tumors with RAS Pathway Alterations
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Paclitaxel-Loaded Tumor Penetrating Microparticles for the Treatment of Peritoneal Carcinomatosis
Status: Temporarily Closed to Accrual
Location: University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa